LIVIVO - Search results -

Search results

Result 1 - 10 of total 34193

Search options

Article ; Online: Constitutive activation mechanism of a class C GPCR.

Shin, Jinwoo / Park, Junhyeon / Jeong, Jieun / Lam, Jordy Homing / Qiu, Xingyu / Wu, Di / Kim, Kuglae / Lee, Joo-Youn / Robinson, Carol V / Hyun, Jaekyung / Katritch, Vsevolod / Kim, Kwang Pyo / Cho, Yunje

Nature structural & molecular biology

2024 Volume 31, Issue 4, Page(s) 678–687

Abstract: Class C G-protein-coupled receptors (GPCRs) are activated through binding of agonists to the large ... extracellular domain (ECD) followed by rearrangement of the transmembrane domains (TMDs). GPR156, a class C ...

Abstract	Class C G-protein-coupled receptors (GPCRs) are activated through binding of agonists to the large extracellular domain (ECD) followed by rearrangement of the transmembrane domains (TMDs). GPR156, a class C orphan GPCR, is unique because it lacks an ECD and exhibits constitutive activity. Impaired GPR156-G
MeSH term(s)	Humans ; Cryoelectron Microscopy ; Receptors, G-Protein-Coupled/metabolism ; Signal Transduction ; GTP-Binding Proteins/metabolism ; Phospholipids
Chemical Substances	Receptors, G-Protein-Coupled ; GTP-Binding Proteins (EC 3.6.1.-) ; Phospholipids
Language	English
Publishing date	2024-02-08
Publishing country	United States
Document type	Journal Article
ZDB-ID	2126708-X
ISSN	1545-9985 ; 1545-9993
ISSN (online)	1545-9985
ISSN	1545-9993
DOI	10.1038/s41594-024-01224-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4101: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 56: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Identification of the novel HLA-C*03:648 allele by next generation sequencing.

Du, Zeying / Williams, Charles / Robinson, Terrence / Hardage, Brittney / Elrefaei, Mohamed

HLA

2023 Volume 103, Issue 1, Page(s) e15324

Abstract: HLA-C*03:648 differs from HLA-C*03:04:02 by one nucleotide substitution at Codon -23 (CGG > CTG ...

Abstract	HLA-C03:648 differs from HLA-C03:04:02 by one nucleotide substitution at Codon -23 (CGG > CTG) in exon 1.
MeSH term(s)	Humans ; HLA-C Antigens/genetics ; High-Throughput Nucleotide Sequencing ; Alleles ; Genes, MHC Class I ; Exons/genetics
Chemical Substances	HLA-C Antigens
Language	English
Publishing date	2023-12-11
Publishing country	England
Document type	Journal Article
ZDB-ID	2845111-9
ISSN	2059-2310 ; 2059-2302
ISSN (online)	2059-2310
ISSN	2059-2302
DOI	10.1111/tan.15324
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 661: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Genome-wide association analysis of cystatin-C kidney function in continental Africa.

Mayanja, Richard / Machipisa, Tafadzwa / Soremekun, Opeyemi / Kamiza, Abram B / Kintu, Christopher / Kalungi, Allan / Kalyesubula, Robert / Sande, Obondo J / Jjingo, Daudi / Fabian, June / Robinson-Cohen, Cassianne / Franceschini, Nora / Nitsch, Dorothea / Nyirenda, Moffat / Zeggini, Eleftheria / Morris, Andrew P / Chikowore, Tinashe / Fatumo, Segun

EBioMedicine

2023 Volume 95, Page(s) 104775

Abstract: ... in Sub-Saharan Africa, with eGFR based on cystatin-C (eGFRcys) exhibiting significantly superior ...

Abstract	Background: Chronic kidney disease is becoming more prevalent in Africa, and its genetic determinants are poorly understood. Creatinine-based estimated glomerular filtration rate (eGFR) is commonly used to estimate kidney function, modelling the excretion of the endogenous biomarker (creatinine). However, eGFR based on creatinine has been shown to inadequately detect individuals with low kidney function in Sub-Saharan Africa, with eGFR based on cystatin-C (eGFRcys) exhibiting significantly superior performance. Therefore, we opted to conduct a GWAS for eGFRcys. Methods: Using the Uganda Genomic Resource, we performed a genome-wide association study (GWAS) of eGFRcys in 5877 Ugandans and evaluated replication in independent studies. Subsequently, putative causal variants were screened through Bayesian fine-mapping. Functional annotation of the GWAS loci was performed using Functional Mapping and Annotation (FUMA). Findings: Three independent lead single nucleotide polymorphisms (SNPs) (P-value <5 × 10 Interpretation: Our study found two previously unreported associated SNPs for eGFRcys in continental Africans (rs59288815 and rs4277141) and validated a previously well-established SNP (rs911119) for eGFRcys. The identified gene-set enrichment for the G-protein signalling pathways relates to the capacity of the kidney to readily adapt to an ever-changing environment. Additional GWASs are required to represent the diverse regions in Africa. Funding: Wellcome (220740/Z/20/Z).
MeSH term(s)	Humans ; Bayes Theorem ; Creatinine ; Cystatin C/genetics ; Genome-Wide Association Study ; Kidney/physiology ; Uganda
Chemical Substances	Creatinine (AYI8EX34EU) ; Cystatin C
Language	English
Publishing date	2023-08-26
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	2851331-9
ISSN	2352-3964
ISSN (online)	2352-3964
DOI	10.1016/j.ebiom.2023.104775
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7090: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: C. elegans mpk-1b

Robinson-Thiewes, Sarah / Kimble, Judith

microPublication biology

2021 Volume 2021

Language	English
Publishing date	2021-01-14
Publishing country	United States
Document type	Journal Article
ISSN	2578-9430
ISSN (online)	2578-9430
DOI	10.17912/micropub.biology.000350
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Utilising organs from hepatitis C virus PCR-positive donors in Western Australia.

Boan, Peter / Jamboti, Jagadish / Musk, Michael / Lavender, Melanie / Wrobel, Jeremy P / Lee, Felicity / Shah, Amit / Pereira, Lynette A / Robinson, J Owen / Irish, Ashley

Internal medicine journal

2024 Volume 54, Issue 4, Page(s) 678–681

Abstract: We transplanted six solid organs from three hepatitis C virus (HCV) polymerase chain reaction (PCR ...

Abstract	We transplanted six solid organs from three hepatitis C virus (HCV) polymerase chain reaction (PCR)-positive donors during 2018-2023. Recipients were treated with glecaprevir/pibrentasvir or sofosbuvir/velpatasvir for 4-12 weeks, with all six achieving sustained virological response without significant adverse events. As occurs in other jurisdictions, solid organ transplants from HCR PCR-positive donors can be safely utilised in Australia.
MeSH term(s)	Humans ; Hepacivirus/genetics ; Antiviral Agents/therapeutic use ; Western Australia/epidemiology ; Sofosbuvir/therapeutic use ; Tissue Donors ; Polymerase Chain Reaction ; Hepatitis C, Chronic/drug therapy ; Hepatitis C/diagnosis ; Hepatitis C/drug therapy
Chemical Substances	Antiviral Agents ; Sofosbuvir (WJ6CA3ZU8B)
Language	English
Publishing date	2024-03-07
Publishing country	Australia
Document type	Journal Article
ZDB-ID	2045436-3
ISSN	1445-5994 ; 1444-0903
ISSN (online)	1445-5994
ISSN	1444-0903
DOI	10.1111/imj.16345
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 792: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 424: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Fe-C-based materials: synthesis modulation for the remediation of environmental pollutants-a review.

Vega, Robinson / Rong, Rong / Dai, Min / Ali, Imran / Naz, Iffat / Peng, Changsheng

Environmental science and pollution research international

2022 Volume 29, Issue 43, Page(s) 64345–64369

Abstract: ... affecting adsorption, the removal effect, and adsorption mechanism of different pollutants by Fe-C materials ... of Fe-C-based technologies for water and soil remediation and the prediction of the future research ... direction of Fe-C composite materials. ...

Abstract	Presently, the rapid pace in the discovery of emerging aquatic pollutants is increasing the demand for the remediation and treatment of our natural resources. Regarding this, nanotechnology is being considered the potential solution for contaminated water remediation with techniques such as filtration, adsorption, catalysis, and desalination. For this purpose, zerovalent iron (ZVI) is being widely used in the remediation of environmental pollutants due to its large specific surface area and high reactivity. However, ZVI is easy to agglomerate and oxidize, limiting its application in the real environment. Therefore, the present study was designed to discuss the preparation and characterization methods of ZVI composite materials, factors affecting adsorption, the removal effect, and adsorption mechanism of different pollutants by Fe-C materials because the optimization and modification of nano-zero-valent iron is a hot research topic nowadays in this field. Moreover, this paper does also analyze the possibility of the practical application prospects of the team's technology for preparing iron-carbon materials. Thus, this information will be helpful for the development and application of Fe-C-based technologies for water and soil remediation and the prediction of the future research direction of Fe-C composite materials.
MeSH term(s)	Adsorption ; Carbon ; Environmental Pollutants ; Environmental Restoration and Remediation ; Iron ; Soil ; Water ; Water Pollutants, Chemical/analysis
Chemical Substances	Environmental Pollutants ; Soil ; Water Pollutants, Chemical ; Water (059QF0KO0R) ; Carbon (7440-44-0) ; Iron (E1UOL152H7)
Language	English
Publishing date	2022-07-18
Publishing country	Germany
Document type	Journal Article ; Review
ZDB-ID	1178791-0
ISSN	1614-7499 ; 0944-1344
ISSN (online)	1614-7499
ISSN	0944-1344
DOI	10.1007/s11356-022-21849-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Bonn / Germany

Z 5915: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Certolizumab Pegol Efficacy in Patients With Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status: An Analysis From the C-axSpAnd Study.

Robinson, Philip C / Maksymowych, Walter P / Gensler, Lianne S / Hall, Stephen / Rudwaleit, Martin / Hoepken, Bengt / Bauer, Lars / Kumke, Thomas / Kim, Mindy / de Peyrecave, Natasha / Deodhar, Atul

ACR open rheumatology

2022 Volume 4, Issue 9, Page(s) 794–801

Abstract: ... axSpA to show active sacroiliitis on magnetic resonance imaging (MRI) and/or an elevated C-reactive ... in patients with nr-axSpA stratified by baseline MRI/CRP status.: Methods: C-axSpAnd was a phase 3 ...

Abstract	Objective: Tumor necrosis factor inhibitors (TNFi) are an effective treatment for non-radiographic axial spondyloarthritis (nr-axSpA). To be eligible, however, many authorities require patients with nr-axSpA to show active sacroiliitis on magnetic resonance imaging (MRI) and/or an elevated C-reactive protein (CRP) level, possibly resulting in a perception that patients with nr-axSpA without both factors have only low responses to TNFi treatment. We evaluated clinical responses to certolizumab pegol (CZP) in patients with nr-axSpA stratified by baseline MRI/CRP status. Methods: C-axSpAnd was a phase 3, multicenter study on CZP in adult patients with active nr-axSpA and objective signs of inflammation. This analysis assessed efficacy of CZP over the 52-week randomized, double-blind, placebo-controlled period in patients stratified into subgroups based on the presence of active sacroiliitis on MRI and CRP level at baseline. Results: CZP-treated patients across all MRI/CRP subgroups achieved clinical responses greater than placebo. Across outcome measures, CZP-treated MRI+/CRP+ patients demonstrated the greatest clinical responses, but substantial improvements were also observed in CZP-treated MRI+/CRP- and MRI-/CRP+ patients. Ankylosing Spondylitis Disease Activity Score Major Improvement response rates at week 52 among CZP-treated patients (75.6% MRI+/CRP+; 47.5% MRI-/CRP+; and 29.7% MRI+/CRP-) were higher than rates in placebo groups (range: 3.9%-12.5%). Assessment of SpondyloArthritis international Society 40% response, Bath Ankylosing Spondylitis Disease Activity Index, and Bath Ankylosing Spondyloarthritis Functional Index had similar response patterns, although differences between the CZP-treated MRI/CRP subgroups were smaller. Clinical responses among CZP-treated patients were also observed in additional subgroups, including those with low Spondyloarthritis Research Consortium of Canada MRI sacroiliac joint inflammation scores and those with normal baseline CRP levels. Conclusion: Our findings indicate that CZP treatment benefits patients with nr-axSpA across MRI+/CRP+, MRI-/CRP+, and MRI+/CRP- subgroups.
Language	English
Publishing date	2022-06-22
Publishing country	United States
Document type	Journal Article
ISSN	2578-5745
ISSN (online)	2578-5745
DOI	10.1002/acr2.11469
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: The Effect of Etanercept in Nonradiographic Axial Spondyloarthritis by Stratified C-Reactive Protein Levels.

Tam, Hoi Ki Joshua / Nash, Peter / Robinson, Philip C

ACR open rheumatology

2021 Volume 3, Issue 10, Page(s) 699–706

Abstract: Objective: Biological agents have shown markedly different response rates by baseline C-reactive ... outcomes by baseline C-reactive protein (CRP) level of less than 5 mg/L, 5 mg/L to 10 mg/L, and greater ...

Abstract	Objective: Biological agents have shown markedly different response rates by baseline C-reactive protein (CRP). Here, we determine the response of patients with nonradiographic axial spondyloarthritis (nr-axSpA) to etanercept stratified by their baseline CRP level. Methods: The EMBARK trial was a phase 3, randomized, double-blind, placebo-controlled study of etanercept in nr-axSpA. The primary endpoint was Assessment of Spondyloarthritis International Society (ASAS) 40 at Week 12, the conclusion of the double-blind phase. It recruited patients who met the ASAS criteria for axial spondyloarthritis, and sacroiliac joint magnetic resonance scans were completed on all patients. In this post hoc analysis, we analyzed outcomes by baseline C-reactive protein (CRP) level of less than 5 mg/L, 5 mg/L to 10 mg/L, and greater than 10 mg/L. The clinical trial outcome data were accessed via the Vivli platform. Results: In the less than 5 mg/L CRP group treated with etanercept, the ASAS20 response, ASAS40 response, Ankylosing Spondylitis Disease Activity Score-CRP (ASDAS-CRP), and ASDAS-ESR (erythrocyte sedimentation rate) outcomes were 49% (P = 0.84), 26% (P = 0.14), 42% (P = 0.002), and 44% (P = 0.006), respectively. In the 5 to 10 mg/L CRP group treated with etanercept, the ASAS20 response, ASAS40 response, ASDAS-CRP, and ASDAS-ESR outcomes were 56% (P = 0.99), 31% (P = 0.40), 56% (P = 0.16), and 50% (P = 0.11), respectively. In the greater than10 mg/L CRP group treated with etanercept, the ASAS20 response, ASAS40 response, ASDAS-CRP, and ASDAS-ESR outcomes were 74% (P = 0.02), 68% (P = 0.003), 82% (P = 0.005), and 50% (P = 0.001), respectively. Conclusion: Although there are reduced ASAS20 and ASAS40 response rates in the groups with baseline CRP less than 10 mg/L, there remain clinically relevant responses when the composite outcome measures ASDAS-CRP or ASDAS-ESR were used, and this should be considered when deciding on thresholds for reimbursement.
Language	English
Publishing date	2021-08-18
Publishing country	United States
Document type	Journal Article
ISSN	2578-5745
ISSN (online)	2578-5745
DOI	10.1002/acr2.11312
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Incarceration, Inequality, and Hepatitis C Treatment: The Story of Two Southern States.

Wennerstrom, Ashley / Manogue, Sean / Hardeo, Hannah / Robinson, William T / Thomas, David L / Irvin, Risha

Journal of health care for the poor and underserved

2023 Volume 34, Issue 3, Page(s) 1129–1135

Abstract: Hepatitis C virus (HCV) infection causes liver-related morbidity/mortality and disproportionately ...

Abstract	Hepatitis C virus (HCV) infection causes liver-related morbidity/mortality and disproportionately affects people who are incarcerated and non-Hispanic Black populations, largely due to social and policy issues that contribute to poor health. With the advent of highly efficacious treatment, HCV is now curable. However, most states' departments of corrections do not offer universal HCV testing or treatment. Two southern states-Tennessee and Louisiana-provide examples of divergent approaches to addressing HCV infection. While Tennessee has offered treatment on a limited basis, resulting in a class action lawsuit, the state of Louisiana recently adopted a new approach. In establishing the 2019 Hepatitis Elimination Plan, the state created a standard of care for HCV infection that included robust testing and treatment in state prison facilities while capping costs. Louisiana has demonstrated the feasibility of HCV testing and treatment programs within state prisons, an important step towards achieving health equity.
MeSH term(s)	Humans ; Health Equity ; Hepacivirus ; Hepatitis C/diagnosis ; Hepatitis C/epidemiology ; Hepatitis C/therapy ; Prisons ; Black or African American ; Healthcare Disparities ; Louisiana ; Tennessee
Language	English
Publishing date	2023-11-28
Publishing country	United States
Document type	Journal Article
ZDB-ID	1142637-8
ISSN	1548-6869 ; 1049-2089
ISSN (online)	1548-6869
ISSN	1049-2089
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3605: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 493: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Yields and product comparison between Escherichia coli BL21 and W3110 in industrially relevant conditions: anti-c-Met scFv as a case study.

Arauzo-Aguilera, Klaudia / Buscajoni, Luisa / Koch, Karin / Thompson, Gary / Robinson, Colin / Berkemeyer, Matthias

Microbial cell factories

2023 Volume 22, Issue 1, Page(s) 104

Abstract: Introduction: In the biopharmaceutical industry, Escherichia coli is one of the preferred expression hosts for large-scale production of therapeutic proteins. Although increasing the product yield is important, product quality is a major factor in this ... ...

Abstract	Introduction: In the biopharmaceutical industry, Escherichia coli is one of the preferred expression hosts for large-scale production of therapeutic proteins. Although increasing the product yield is important, product quality is a major factor in this industry because greatest productivity does not always correspond with the highest quality of the produced protein. While some post-translational modifications, such as disulphide bonds, are required to achieve the biologically active conformation, others may have a negative impact on the product's activity, effectiveness, and/or safety. Therefore, they are classified as product associated impurities, and they represent a crucial quality parameter for regulatory authorities. Results: In this study, fermentation conditions of two widely employed industrial E. coli strains, BL21 and W3110 are compared for recombinant protein production of a single-chain variable fragment (scFv) in an industrial setting. We found that the BL21 strain produces more soluble scFv than the W3110 strain, even though W3110 produces more recombinant protein in total. A quality assessment on the scFv recovered from the supernatant was then performed. Unexpectedly, even when our scFv is correctly disulphide bonded and cleaved from its signal peptide in both strains, the protein shows charge heterogeneity with up to seven distinguishable variants on cation exchange chromatography. Biophysical characterization confirmed the presence of altered conformations of the two main charged variants. Conclusions: The findings indicated that BL21 is more productive for this specific scFv than W3110. When assessing product quality, a distinctive profile of the protein was found which was independent of the E. coli strain. This suggests that alterations are present in the recovered product although the exact nature of them could not be determined. This similarity between the two strains' generated products also serves as a sign of their interchangeability. This study encourages the development of innovative, fast, and inexpensive techniques for the detection of heterogeneity while also provoking a debate about whether intact mass spectrometry-based analysis of the protein of interest is sufficient to detect heterogeneity in a product.
MeSH term(s)	Escherichia coli/metabolism ; Single-Chain Antibodies/genetics ; Single-Chain Antibodies/metabolism ; Recombinant Proteins ; Escherichia coli Proteins/metabolism ; Disulfides/metabolism
Chemical Substances	Single-Chain Antibodies ; Recombinant Proteins ; Escherichia coli Proteins ; Disulfides
Language	English
Publishing date	2023-05-19
Publishing country	England
Document type	Journal Article
ZDB-ID	2091377-1
ISSN	1475-2859 ; 1475-2859
ISSN (online)	1475-2859
ISSN	1475-2859
DOI	10.1186/s12934-023-02111-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito